First Warning Systems, Inc., a Reno, Nevada-based provider of a breast tissue screening device, has raised $1m in Series A funding.
Backers include members of the Reno Angels and local investors.
Founded in 2008 and led by CEO Jim Holmes, First Warning Systems holds the exclusive worldwide license from its principal shareholder Lifeline Biotechnologies (OTC Market: LLBO) for development, manufacturing and marketing of the software-based technologies. The company’s line is a patented device and process that detects breast tissue abnormalities for health risk assessment and management earlier than any other known modalities.
Three clinical trials with over 650 participants have achieved proof of concept and superior outcomes with industry leading 90% accuracy. First Warning Systems is planning a final, limited clinical trial and a 510k device classification to validate the fourth generation of the FWS predictive analytics product.
The company is preparing for Euro CE Mark and marketing in the UK, EU and Russian markets.